UPS (NYSE: UPS) opened 27 new temperature-controlled truck cross-dock facilities worldwide, investing $48 million to support pharmaceutical manufacturers, medical laboratories, and biotech customers requiring strict cold-chain integrity. The facilities are strategically placed near major air and multimodal hubs across Europe, Asia, and the Americas. All sites comply with IATA pharmaceutical handling standards and are designed for rapid air-to-ground and ground-to-ground transfers, minimizing traditional warehousing. UPS previously opened two healthcare cross-dock facilities in Milan and Frankfurt in late 2024. The expansion addresses surging demand for cell and gene therapies, mRNA vaccines, and GLP-1 weight-loss drugs, which require tight temperature control and minimal handoffs. Industry forecasts project the temperature-sensitive biologics market to grow at 8.3% CAGR through 2033, reaching $39.1 billion.
Summary
Read original article →